Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Sunrise Air, an FDA-cleared rechargeable home sleep testing device, enables multi-night monitoring of sleep apnea using a minimalist chin sensor rather than traditional clinic-based polysomnography. This approach addresses both the practical barriers to diagnosis and the physiological reality that sleep patterns vary significantly night-to-night, making single-night clinical studies insufficient for accurate apnea detection.
Continuous hormonal monitoring via wearable technology addresses a fundamental gap in women's healthcare: annual or biannual blood tests cannot capture hormonal dynamics that fluctuate hourly and respond to immediate environmental and physiological pressures. This shift from static snapshots to real-time signal interpretation reframes how women's health is understood and managed.
ProHealth introduced Essentials NMN 500, a 500 mg nicotinamide mononucleotide supplement using an amorphous formulation claimed to enhance bioavailability, priced at $24.95 for 30 capsules. Published research supports that NMN supplementation raises blood NAD+ levels within the 250-1,200 mg dose range, though direct clinical comparison data between formulation types remains limited.
An educational intervention combining aging awareness training with structured contact experiences significantly reduced ageist attitudes among healthcare providers in a quasi-experimental design. This finding addresses a critical gap in clinical practice: provider bias directly shapes clinical decision-making, diagnostic thoroughness, and treatment escalation in older patients.
A predictive equation successfully identifies cats with reduced kidney function using non-invasive markers, offering an alternative to standard clinical assessment. Early detection of renal decline in feline populations could extend healthspan through timely intervention before symptomatic disease emerges.
Adherence to the American Heart Association's Life's Essential 8 cardiovascular health metrics predicts mortality risk across the adult lifespan, from middle age through centenarian status. This finding demonstrates that the relationship between cardiovascular function and longevity is not age-dependent but rather persistent, establishing these metrics as durable predictors of survival across decades.
Elevated serum uric acid independently predicts progression to cardiometabolic disease and multimorbidity, with gout serving as a clinical marker of this systemic risk. This relationship persists across metabolic phenotypes, suggesting uric acid operates as a metabolic signal warranting earlier intervention than current clinical thresholds recognize.
China has launched a structured, national physician training program in longevity medicine designed to embed preventive healthspan protocols into mainstream clinical practice across internal medicine, geriatrics, cardiology, and endocrinology. This represents a systemic shift from reactive disease management to prospective health optimization at the healthcare infrastructure level, positioning longevity medicine as an institutional and economic necessity rather than a niche practice.
Phosphatidylcholine, the dominant lipid in mitochondrial membranes, declines with age and drives mitochondrial fragmentation and dysfunction. The decline occurs through reduced activity of S-adenosylmethionine synthetase (SAMS-1), a protein that coordinates phosphatidylcholine synthesis. This pathway represents a modifiable driver of mitochondrial aging with potential intervention points in later life.
Scribe Therapeutics presented preclinical data on epigenetic gene silencing that reduces off-target effects by 10- to 100-fold while maintaining durable therapeutic effects. Their lead program targets PCSK9 for cholesterol reduction, with nonhuman primate data showing sustained effects lasting nearly 18 months after a single treatment—a shift from permanent DNA editing toward controlled, reversible intervention.
Scribe Therapeutics has received regulatory approval to begin human testing of STX-1150, an epigenetic therapy designed to silence PCSK9 and lower LDL cholesterol through a single mRNA-based treatment delivered via lipid nanoparticle to the liver. This represents the first clinical evaluation of a reversible epigenetic silencing approach to cholesterol management, offering potential for sustained LDL reduction without permanent genomic alteration.
BioCardia's autologous bone marrow cell therapy demonstrated sustained improvements in exercise capacity and angina reduction over two years in patients with chronic myocardial ischemia who had exhausted standard interventions. The therapy showed no treatment-emergent major adverse cardiac events, with exercise tolerance gains of 179 seconds persisting through follow-up and angina episodes declining 82% at six months.